CheckMate -577 trial for Opdivo meets primary endpoint of disease-free survival
Bristol Myers Squibb announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as a first-line treatment for…
Read More...
Read More...